Budesonide

證據等級: L5

預測適應症: 10 個

Budesonide: From Asthma to Atopic Eczema

One-Sentence Summary

Budesonide is a synthetic inhaled corticosteroid primarily approved for asthma and inflammatory conditions of the respiratory tract and gastrointestinal mucosa. The TxGNN model predicts it may be effective for Atopic Eczema, with 2 related clinical trials and 20 publications currently identified to support this research direction. However, clinical evidence remains at preclinical level, and a critical safety concern — elevated contact sensitisation rates to budesonide in patients with atopic skin barrier disruption — must be addressed before clinical advancement.

Quick Overview

Item	Content
Original Indication	Asthma and inflammatory mucosal conditions (inhaled/topical corticosteroid)
Predicted New Indication	Atopic Eczema
TxGNN Prediction Score	99.96%
Evidence Level	L4
New Zealand Market Status	Not marketed
Number of Authorisations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not formally available in this evidence pack. Based on known pharmacology, budesonide is a potent synthetic glucocorticoid receptor (GR) agonist. It suppresses inflammation primarily by inhibiting NF-κB signalling, downregulating pro-inflammatory cytokines (IL-4, IL-5, IL-13), and reducing eosinophil recruitment to affected tissue. These effects are well-established across multiple mucosal sites — from the airways in asthma to the intestinal wall in Crohn's disease.

Atopic eczema is driven by Th2-skewed inflammation characterised by elevated IL-4 and IL-13 signalling, which disrupts skin barrier proteins (filaggrin, claudins) and sustains chronic pruritic lesions. This inflammatory pathway directly overlaps with budesonide's known anti-inflammatory targets, providing a strong biological rationale for the TxGNN model's prediction. The mechanistic link is reinforced by a 2025 mechanistic review (PMID 40284499) confirming budesonide's broad mucosal anti-inflammatory activity, explicitly covering dermatological and gastrointestinal applications beyond the respiratory tract.

The key challenge lies in drug delivery. Conventional topical corticosteroids penetrate atopic skin poorly and carry systemic absorption risks, particularly in children. A 2024 preclinical study (PMID 38275852) specifically addressed this by formulating budesonide-loaded Eudragit L100 pH-sensitive nanoparticles into hydrogels, exploiting the characteristic pH shift in atopic lesions to achieve targeted local drug release. This novel delivery platform directly addresses the main barrier to topical budesonide use in AD and represents a promising investigational path. However, an important safety paradox exists: patients with atopic dermatitis have significantly elevated rates of contact hypersensitivity to budesonide itself — a signal that must be characterised before topical application can be safely pursued.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT01028560	Phase 1/2	Completed	58	Allergy immunotherapy in atopic wheezing children (18 months–3 years) at high risk for asthma; participants carry atopic phenotypes including eczema and food allergy, providing an indirect Th2-driven atopic cohort relevant to understanding immunological response in this population
NCT04680117	N/A	Unknown	150	Characterisation of severe paediatric asthma endotypes through immune, metabolomic and microbiota profiling; includes atopic phenotyping but primary focus is airway disease, not eczema treatment — limited direct relevance

Literature Evidence

PMID	Year	Type	Journal	Key Findings
38275852	2024	Formulation/Preclinical	Gels	Budesonide-loaded Eudragit L100 pH-sensitive nanoparticles in hydrogel form for paediatric AD local therapy; exploits atopic lesion pH shift to achieve targeted release — proof-of-concept for overcoming topical delivery barrier
9496795	1998	Clinical Study	Pediatric Dermatology	Knemometry study in 14 AD children (aged 5–12) treated with topical budesonide across 6-week open trial; assessed short-term lower-leg growth impact — key paediatric safety benchmark
8864369	1996	Clinical Study	Dermatology	IGF axis, bone and collagen turnover in AD children receiving topical glucocorticosteroids; demonstrates systemic absorption via percutaneous route with growth-suppressive implications — critical for paediatric safety profiling
21062310	2010	Animal RCT	J Vet Pharmacol Ther	Randomised, blinded, placebo-controlled crossover study of 0.025% budesonide leave-on conditioner (Barazone) in 29 dogs with AD; significantly reduced skin lesions and pruritus — closest available controlled evidence of topical budesonide efficacy in AD
19875223	2010	Clinical Cohort	Allergologia et Immunopathologia	Differential budesonide response in atopic versus non-atopic infants with recurrent wheezing; atopic phenotype showed distinct corticosteroid responsiveness — indirect support for budesonide activity in Th2-driven disease
33931866	2021	Epidemiological	Contact Dermatitis	Italian SIDAPA patch test series (2018–2019); budesonide is the European standard marker for corticosteroid hypersensitivity — a declining allergy trend observed over 20 years, with implications for topical use safety in AD
35133669	2022	Cross-sectional	Contact Dermatitis	Asian dermatology centre data on contact sensitisation rates in AD vs. non-AD patients; challenges the traditional assumption that AD reduces sensitisation risk — directly relevant to budesonide topical safety in this population
30053491	2018	Cross-sectional	J Am Acad Dermatol	Contact dermatitis to topical medications including corticosteroids in adults with AD; skin barrier disruption in AD significantly increases sensitisation risk — a key safety signal for the proposed indication
24603519	2014	Cross-sectional	Dermatitis	Contact hypersensitivity to the corticosteroid patch-test series in adolescents and adults with AD; budesonide allergy rates documented in this specific population — quantifies the treatment paradox risk
19571596	2009	Review	Neuroimmunomodulation	Intranasal corticosteroids and HPA axis suppression; AD frequently co-exists with rhinitis and asthma, so cumulative corticosteroid exposure from multiple routes is a real clinical concern requiring monitoring

New Zealand Market Information

Budesonide is currently not registered or marketed in New Zealand. No product authorisations are on file. Clinical use data, approved indications, and local prescribing information are not available from the New Zealand regulatory database.

Safety Considerations

Please refer to the package insert for safety information.

Note: Two data gaps were identified that limit safety assessment. TFDA (Taiwan) package insert warnings and contraindications (DG001, Blocking severity) could not be retrieved, preventing formal safety screening. DrugBank MOA and interaction data (DG002, High severity) are also missing. These gaps must be resolved before safety evaluation can proceed.

Conclusion and Next Steps

Decision: Hold

Rationale: The TxGNN model's 99.96% prediction score for budesonide in atopic eczema is mechanistically credible — the Th2/IL-4/IL-13 inflammatory axis targeted by budesonide is central to AD pathology. However, clinical evidence is currently at L4 (preclinical/mechanism level only), with no completed human trials directly evaluating budesonide as an AD treatment. Critically, patients with atopic dermatitis have documented elevated contact sensitisation rates to budesonide due to impaired skin barrier function, creating a safety paradox that must be characterised before any topical clinical programme is initiated.

To proceed, the following is needed:

Retrieve full package insert safety data (warnings, contraindications) — DG001 is currently blocking formal safety evaluation
Obtain MOA data from DrugBank — DG002 limits mechanistic analysis depth
Conduct a systematic review of budesonide contact sensitisation rates specifically in AD patients, to quantify the treatment paradox risk
Initiate a Phase 1 human skin safety and pharmacokinetics study using the novel nanoparticle hydrogel formulation described in PMID 38275852, to establish whether targeted delivery can reduce sensitisation risk
Commission a regulatory pathway review with Medsafe (New Zealand), given that budesonide currently has no New Zealand product authorisations and a new indication would require a full dossier submission
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.